Ropeginterferon alfa-2b: all 34 studies that test it

Page 1 of 1. Open to participants first (9), then studies with results posted, then the rest; newest registration first within each.

• A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 MutationsRecruitingNCT07646821Phase 1/2
• Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in MyelofibrosisRecruitingNCT07521046Phase 1
• Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic LeukemiaNot yet recruitingNCT07468916Phase 2
• Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)RecruitingNCT07047885Phase 1
• Ropeginterferon Alfa 2b Plus Ruxolitinib for MyelofibrosisRecruitingNCT06770842Phase 2
• Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With ComorbiditiesNot yet recruitingNCT05808322Phase 2/3
• Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk MyelofibrosisRecruitingNCT05731245Phase 2
• Ropeginterferon Alfa 2b for Early MyelofibrosisRecruitingNCT04988815Phase 2
• Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET PatientsRecruitingNCT04655092Phase 3
• Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to ApplyCompletedNCT04182100Phase 2Results posted
• P1101 in Treating Patients With MyelofibrosisTerminatedNCT02370329Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia PatientsActive, not recruitingNCT06514807Phase 3
• P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 RiskActive, not recruitingNCT06468033Phase 3
• Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia VeraWithdrawnNCT06290765Phase 4
• A Study to Evaluate P1101 in Japanese PV PatientsCompletedNCT06002490Phase 3
• Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19.CompletedNCT05770466Phase 3
• Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue TherapyStatus unknownNCT05494528Not applicable
• A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HUActive, not recruitingNCT05485948Phase 2
• A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ETActive, not recruitingNCT05482971Phase 2
• A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PVActive, not recruitingNCT05481151Phase 3
• Single Dose Escalation Study of P1101 in Healthy Adult Male SubjectsCompletedNCT05129644Phase 1
• The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 InfectionCompletedNCT04774107Phase 1
• The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D InfectionCompletedNCT04638439Phase 1
• Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 InfectionCompletedNCT04382937Phase 3
• Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or IntoleranceActive, not recruitingNCT04285086Phase 3
• P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular CarcinomaStatus unknownNCT04233840Phase 1/2
• Safety, Tolerability, Pharmacokinetics & Pharmacodynamics Study of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian SubjectsCompletedNCT03546465Phase 1
• The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PVCompletedNCT03003325Phase 2
• Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera PatientsCompletedNCT02523638Phase 3
• AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.CompletedNCT02218047Phase 3
• Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia VeraCompletedNCT01949805Phase 3
• Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular ResponseCompletedNCT01933906Phase 1
• Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With Hepatitis C Virus Genotype 1 InfectionCompletedNCT01587586Phase 2
• Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia VeraCompletedNCT01193699Phase 1/2

← Ropeginterferon alfa-2b overview